Compound class:
Synthetic organic
Comment: ERW1041E is a transglutaminase inhibitor [3]. We drew the structure as depicted in Chrobok et al. (2018) [1], with the indicated stereochemistry (but note that the IUPAC they provide is for the flat structure that is represented by PubChem CID 11619556).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
ERW1041E inhibits transglutaminase 1 (TGM1) with an in vitro IC50 of 440 nM, and the related transglutaminase factor XIII A chain (F13A1) with an IC50 of 52000 nM [1]. In a mouse model of intestinal inflammation (polyinosinic-polycytidylic acid-induced enteropathy and activation of transglutaminase 2), ERW1041E reduced transglutaminase 2 activity [2]. In the EAE MS model ERW1041E reduced disease motor-symptoms but did not alter inflammation related markers in the spinal cord, immune cell influx or transglutaminase activity . [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|